Kooperativer Bibliotheksverbund

UID:

Format: 1 Online-Ressource (XIX, 680 Seiten) : , Illustrationen.

ISBN: 978-981-1919-46-6

In: Role of microorganisms in pathogenesis and management of autoimmune diseases.

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-45-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-47-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-48-0

Language: English

DOI: 10.1007/978-981-19-1946-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Language: English

Author information: Shoenfeld, Yehuda 1948-

UID:

Format: 1 Online-Ressource (XIX, 680 Seiten) : , Illustrationen.

ISBN: 978-981-1919-46-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-45-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-47-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-48-0

Language: English

DOI: 10.1007/978-981-19-1946-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XIX, 680 Seiten) : , Illustrationen.

ISBN: 978-981-1919-46-6

In: Role of microorganisms in pathogenesis and management of autoimmune diseases.

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-45-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-47-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-48-0

Language: English

DOI: 10.1007/978-981-19-1946-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 Online-Ressource (XIX, 680 Seiten) : , Illustrationen.

ISBN: 978-981-1919-46-6

In: Role of microorganisms in pathogenesis and management of autoimmune diseases.

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-45-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-47-3

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-1919-48-0

Language: English

DOI: 10.1007/978-981-19-1946-6

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (1120 pages)

Edition: 3rd ed.

ISBN: 0-323-99131-9

Note: Intro -- Infection and Autoimmunity -- Copyright -- Contents -- Contributors -- Chapter 1: Infection and Autoimmunity - An Introductory Note -- 1. Introduction -- 2. Autoimmunity Versus Autoimmune Disease -- 3. An Animal Model-Based Theory -- 4. The Example of COVID-19 -- 5. The Example of Acute Rheumatic Fever -- 6. The Example of Systemic Lupus Erythematosus -- 7. Conclusion -- References -- Part 1: Mechanisms in Infections and Autoimmunity -- Chapter 2: Molecular Mimicry and Autoimmunity in a Glance -- 1. Introduction -- 2. Common Infectious Agents and Their Role in Setting Autoimmune Disorders -- 2.1. Viruses -- 2.2. Bacteria -- 2.3. Parasites -- 3. Vice Versa - Autoimmune Diseases and Implicated Pathogens -- 3.1. Neuro-Autoimmune Diseases -- 3.2. Endocrinological Autoimmune Diseases -- 4. Rheumatic Autoimmune Diseases -- References -- Chapter 3: Perspectives on Molecular Mimicry Between Human, SARS-CoV-2, and Plasmodium Species Through a Probabil -- 1. Introduction -- 2. Identification of Similar or the Same Human and SARS-CoV-2 Peptide Sequence Pairs -- 3. HLA Binding Strength Predictions -- 4. Discussion Through a Probabilistic and Evolutionary Insight -- 5. Conclusion -- References -- Chapter 4: Molecular Mimicry Study Between Peptides of SARS-CoV-2 and Neutrophil Extracellular Traps-Related Proteins -- 1. Introduction -- 1.1. Identification of Human and SARS-CoV-2 Sequence Pairs -- 1.2. HLA Binding Strength Predictions of Selected Sequence Pairs -- 2. Conclusion -- References -- Chapter 5: Epitope Spreading in Autoimmune Diseases -- 1. Introduction -- 2. Examples of Epitope Spreading in Autoimmune Diseases -- 2.1. Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis -- 2.2. Insulin-Dependent Diabetes Mellitus or Type 1 Diabetes -- 2.3. Rheumatoid Arthritis -- 2.4. Systemic Lupus Erythematosus -- 2.5. Other Autoimmune Diseases. , 2.6. Epitope Spreading Unrelated to the Disease Process or No Spreading During the Disease Course -- 3. Mechanisms Underlying Epitope Spreading During the Course of an Autoimmune Disease -- 3.1. Release of Self-Antigens and Their Processing and Presentation Following Tissue Damage in the Course of a Microbial ... -- 3.2. The Generation of Neo-epitopes via Post-Translational Modification of Antigens and Other Mechanisms -- 3.3. Upregulation of the Display of Cryptic/Sub-Dominant Epitopes Within a Self-Antigen Under Inflammatory Conditions -- 3.4. The Frequency and Avidity of Epitope-Specific Precursor T Cells Within the Mature T-Cell Repertoire Favoring Respons ... -- 3.5. Presentation of Self-Antigens/Epitopes by the B Cells and T Cell-B Cell Interaction -- 3.6. The Influence of Antigen-Bound Antibodies on the Processing and Presentation of T-Cell Epitopes Within That Antigen -- 3.7. Antigen Cross-Presentation to Activate CD8 T Cells and Epitope Spreading -- 3.8. Site of Initiation of Epitope Spreading: Target Organ Versus Periphery -- 4. Concluding Remarks -- Acknowledgments -- References -- Chapter 6: Infections and B1 Cells -- 1. Introduction -- 2. Characteristics of B1 Cells -- 2.1. Ontogeny -- 2.2. B1-Cell Distribution -- 2.3. B1 Cells Produce Self- and Poly-Reactivity -- 2.4. B1 Cells and Antigen Presentation -- 3. CD5 Molecule -- 3.1. CD5 Gene and Transcripts -- 3.2. CD5 Expression Regulation -- 3.3. CD5 Functions -- 3.3.1. CD5 Controls BCR Signaling -- 3.3.2. CD5 Controls IL-10 Production and Anergy -- 3.3.3. Regulatory B Cells -- 4. B1 Cells and Disease -- 4.1. CD5+/B1a and Infectious States -- 4.2. CD20(+)CD27(+)CD43(+)CD5(+/-)/B1 and Infectious States -- 4.3. CD19(+)CD5(+)CD1d(+)IL-10 Regulatory B10 and Infectious States -- 5. Conclusion -- References -- Chapter 7: Anti-Saccharomyces cerevisiae Antibodies and Autoimmune Diseases. , 1. Crohns Disease -- 2. Behcets Disease -- 3. Celiac Disease -- 4. Ankylosing Spondylitis -- 5. Autoimmune Liver Diseases -- 6. Systemic Lupus Erythematosus and Anti-phospholipid Syndrome -- 7. Other Autoimmune Diseases -- References -- Chapter 8: Lymphocytes and Infection in Autoimmune Diseases -- 1. Introduction -- 2. Lymphocytes and Their Subsets in Autoimmune Diseases -- 2.1. T Cells in Autoimmune Diseases -- 2.2. B Cells in Autoimmune Diseases -- 2.3. Natural Killer Cells in Autoimmune Diseases -- 2.4. NKT Cells -- 3. Lymphocyte Subsets and Infection in Autoimmune Diseases -- 4. Causes of Lymphopenia in Autoimmune Diseases -- 4.1. Autoimmune Diseases -- 4.2. Inborn Errors of Immunity/Primary Immunodeficiencies -- 4.3. Infections -- 4.4. Immunosuppressive Therapy and Other Drugs -- 4.4.1. Conventional Disease-Modifying Antirheumatic Drugs -- 4.4.1.1. Steroids -- 4.4.1.2. Methotrexate -- 4.4.1.3. Thiopurines (Azathioprine and 6-Mercaptopurine) -- 4.4.1.4. Mycophenolate Mofetil -- 4.4.1.5. Leflunomide -- 4.4.1.6. Anti-Calcineurin Agents -- 4.4.1.7. Cyclophosphamide -- 4.4.1.8. Hydroxychloroquine -- 4.4.1.9. Sulfasalazine and Mesalamine -- 4.4.2. Targeted Synthetic Disease-Modifying Antirheumatic Drugs -- 4.4.2.1. JAK Inhibitors -- 4.4.2.2. Inhibitor of Phosphodiesterase 4 -- 4.4.3. Biologic Disease-Modifying Antirheumatic Drugs -- 4.4.3.1. Immunoglobulins -- 4.4.3.2. Anti-TNF Biologics -- 4.4.3.3. Anti-Cytokines Non-TNF Biologics -- 4.4.3.4. T and B Cells Targeting Drugs -- Anti-CD20 -- Anti-CTLA4 -- 4.4.4. MS Disease-Modifying Antirheumatic Drugs -- 4.4.4.1. Immunomodulation -- Glatiramer Acetate -- Interferons -- Dimethyl Fumarate -- 4.4.4.2. Targeting Lymphocyte Proliferation -- Teriflunomide -- 4.4.4.3. Targeting Lymphocyte Migration -- Shingoine-1-Phosphate Receptor Modulation: Fingolimod -- α-Integrin Inhibitors: Natalizumab. , 4.4.4.4. Lysis of Specific Lymphocytes Subsets -- Ocrelizumab and Ofatumumab -- Alemtuzumab -- Cladribine -- 5. Preventing Infection in Lymphopenic Autoimmune Patients -- 5.1. Reactivation of Hepatitis B Virus -- 5.2. John Cunningham Virus -- 5.3. Herpes Virus Infection -- 5.3.1. Cytomegalovirus -- 5.3.2. Herpes Simplex 1 and 2 Viruses (HSV 1-2) -- 5.3.3. Varicella-Zoster Virus -- 5.4. Pneumocystis jirovecii Pneumonia -- 5.5. Listeria-Associated Infections -- 5.6. Vitamin D -- 5.7. General Approach -- References -- Chapter 9: Infections and Endothelial Cell Autoreactivity -- 1. Introduction -- 2. Methodological Approaches and Pitfalls in AECA Detection -- 2.1. Methodological Approaches -- 2.2. Pitfalls -- 2.3. Ongoing Strategies -- 3. AECA and Infections -- 3.1. Viral Infections -- 3.2. Bacterial Infections -- 3.3. Parasitic Infections -- 4. Pathogenic Effects of AECA: Lessons From Autoimmune Diseases -- 4.1. EC Colonization -- 4.2. Molecular Mimicry -- 4.3. Neutralizing AECA -- 5. The Targets of AECA in Infectious Diseases -- 5.1. Heat Shock Protein Autoantibodies -- 5.2. Alpha-Enolase, Vimentin -- 6. Conclusions -- Acknowledgments -- References -- Chapter 10: Infection and Inflammation: A Double-Edged Sword -- 1. Introduction -- 2. COVID-19 -- 2.1. The Diverse Clinical Course of the Disease -- 2.2. The Complex Inflammatory Response to COVID-19 -- 3. Shigellosis -- 3.1. Neurologic Manifestations of Shigellosis -- 3.2. Inflammatory Response to Shigella in Humans and in a Mouse Model -- 4. Host Inflammatory Response as an Aid in Diagnosis -- 4.1. Acute Infection: Bacterial or Viral? -- 4.2. Host Inflammatory Response as an Aid to Distinguish Between Bacterial and Viral Infections -- 4.3. ``Host-Protein Signature to Infection´´ -- References -- Chapter 11: Infection, Autoimmunity, and Vitamin D -- 1. Introduction -- 2. Vitamin D and Immunity. , 2.1. Vitamin D and the Innate Immune System -- 2.2. Dendritic Cells and Vitamin D -- 2.3. Vitamin D and Adaptive Immunity -- 3. Infection and Vitamin D -- 3.1. Tuberculosis -- 3.2. Leprosy (Hansens Disease) -- 3.3. Respiratory Infections -- 3.4. Urinary Infections -- 3.5. Human Immunodeficiency Virus -- 3.6. SARS-CoV-2 -- 4. Vitamin D and Autoimmunity -- 5. Vitamin D and Autoimmune Diseases -- 5.1. Vitamin D Deficiency and Rheumatoid Arthritis -- 5.2. Vitamin D Deficiency and Systemic Lupus Erythematosus -- 5.3. Vitamin D Deficiency and Type 1 Diabetes Mellitus -- 5.4. Vitamin D Deficiency and Multiple Sclerosis -- 5.5. Vitamin D and Inflammatory Bowel Disease -- 5.6. Vitamin D Deficiency and Autoimmune Hashimotos Thyroiditis -- 5.7. Vitamin D Deficiency and Systemic Sclerosis -- 6. Optimal Levels of 25(OH)D3 -- 7. Conclusions -- References -- Chapter 12: Seasonality and Autoimmunity -- 1. Introduction -- 2. Seasonality and Immune System -- 3. Seasonality, Infections, and Autoimmunity -- 4. Vitamin D, Sun Exposure, and Autoimmunity -- 5. Melatonin, Seasonality, and Immune System -- 6. Seasonality in Autoimmune Diseases - Infectious Agents, Vitamin D, and Melatonin -- 6.1. Type 1 Diabetes Mellitus -- 6.2. Multiple Sclerosis -- 6.3. Narcolepsy -- 6.4. Autoimmune Thyroid Disorders -- 6.5. Systemic Lupus Erythematosus -- 6.6. Rheumatoid Arthritis -- 6.7. Spondyloarthritis and Uveitis -- 6.8. Juvenile Arthritis -- 6.9. Rheumatic Fever and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections -- 6.10. Polymyalgia Rheumatica and Temporal Arteritis -- 6.11. Myositis -- 6.12. IBD and Celiac Disease -- 6.13. Cutaneous Diseases -- 6.14. Allergy -- 6.15. Seasonal Affective Disorder -- 7. Conclusion -- Further Reading -- Part 2: Viruses and Autoimmunity. , Chapter 13: Autoimmunity on the Rise: COVID-19 as a Trigger of Autoimmunity.

Additional Edition: Print version: Shoenfeld, Yehuda Infection and Autoimmunity San Diego : Elsevier Science & Technology,c2023 ISBN 9780323991308

Language: English

UID:

Format: XIV, 886 S. : , Ill., graph. Darst.

ISBN: 978-1-57331-762-7 , 1-57331-762-4

Series Statement: Annals of the New York Academy of Sciences 1173

Language: English

Subjects: Medicine

Keywords: Autoimmunität ; Konferenzschrift ; Konferenzschrift

URL: http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018672579&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA

URL: Volltext  (Electronic Version: Web page with links to scanned depiction of full text and images)

Author information: Shoenfeld, Yehuda, 1948-

UID:

Language: English

Author information: Shoenfeld, Yehuda 1948-

UID:

Language: English

Author information: Shoenfeld, Yehuda 1948-

UID:

Format: 1 online resource (467 p.)

Edition: 1st ed.

ISBN: 1-281-01901-1 , 9786611019013 , 0-08-052845-7 , 1-4356-0114-9

Content: Of the two disciplines in parallel development for two decades, tumor immunology and transplantation immunology, the latter has thrived and has led to some of the most critical discoveries in immunobiology. The former continues to thwart both scientists and clinicians alike. The goal of immunologists in modern day research is to develop a simple and effective means to manipulate cancer in vivo, possibly encompassing several venues: identifying a phenotypic marker and the use of either active or passive immunization; include the use of passive reagents carrying ""warheads"" to select

Note: Description based upon print version of record. , Front Cover; Cancer and Autoimmunity; Copyright Page; Contents; Preface; List of Contributors; Introduction: The Immune System, the Autoimmune State and Autoimmune Disease; Part I: Malignancies in Autoimmune Diseases; Chapter 1. Rheumatoid Arthritis and Cancer; Chapter 2. SLE and Cancer; Chapter 3. Malignancies Occurring in Scleroderma; Chapter 4. PSS (Scleroderma) and Cancer; Chapter 5. Vasculitis and Malignancy; Chapter 6. Sjögren's Syndrome and Lymphoproliferative Disease; Chapter 7. Polymyalgia Rheumatica, Temporal Arteritis and Occurrence of Malignant Tumors , Chapter 8. Myositis and Neoplasia Chapter 9. Antiphospholipid Antibodies and Malignancies; Chapter 10. Malignancy in Coeliac Disease and Dermatitis Herpetiformis; Chapter 11. Autoimmune Rheumatic Diseases and Cancer: Evidence of Causality?; Part II: Autoimmunity in Malignant States; Chapter 12. Paraneoplastic Syndromes; Chapter 13. Paraneoplastic Arthritis; Chapter 14. Auto antibodies, Autoimmunity and Cancer; Chapter 15. Antinuclear Antibodies as Potential Markers of Lung Cancer; Chapter 16. Autoantibodies in Cancer Patients and in Persons with a Higher Risk of Cancer Development , Chapter 17. Auto antibodies to the Proliferation-Associated Nuclear Protein CENP-F in Cancer Chapter 18. p53 Auto antibodies and Cancer: Specificity, Diagnosis and Monitoring; Chapter 19. Humoral Immune Response Against the Growth Suppressor p53 in Human Malignancies; Chapter 20. Expression of ETS Family of Genes in Systemic Lupus Erythematosis; Chapter 21. Immune Response to Tumor Stress Proteins-Implications for Vaccine Development Against Cancer; Chapter 22. Autoimmunity and B-Cell Malignancies; Chapter 23. Autoimmunity in B-Lymphoproliferative Disorders , Chapter 24. CD5 Positive B Cells: Crossroads of Autoimmunity and Lymphoid Malignancy Chapter 25. Thymoma and Autoimmune Diseases; Chapter 26. Castleman's Disease and Autoimmunity; Part III: Mechanisms in Cancer and Autoimmunity; Chapter 27. IgA and Cancer; Chapter 28. Apoptosis: The Relation Between Anti-Fas Antibodies, and Immuno surveillance Against Cancer and Autoimmunity; Chapter 29. Hepatitis C Virus, Autoimmunity and Cancer; Chapter 30. The Human Neurotropic Virus, JCV, and Its Association with CNS Tumors; Chapter 31. The Smoking Cancer-Autoimmunity Connection , Chapter 32. Significance and Regulation of the Expression of MHC Class II Molecules on Autoimmune and Neoplastic Thyroid Cells Chapter 33. Cancer Immunity: A Problem of Self-Tolerance; Chapter 34. Maternal Immune Response to Trophoblast, GTD, and Cancer; Part IV: Therapy in Autoimmunity and Cancer-Common and Different Denominators; Chapter 35. Therapy of Cancer and Autoimmunity: Immuno-modulatory Strategies Based on Modified Dendritic Cells; Chapter 36. Anti-Idiotypic Therapy in Autoimmunity , Chapter 37. Active Specific Immuno therapy of Malignant Diseases-Breaking Tolerance to Self-Antigens with Tumor Associated Antigen Mimics , English

Additional Edition: ISBN 0-444-50331-5

Language: English